BRIEF—Change of leadership at ALK

Danish allergy company ALK Abello has announced Carsten Hellman will step down as chief executive, to be replaced by current Fertin Pharma CEO Peter Halling.

Mr Halling, who will take over at the start of next year at the latest, has led Fertin, a contract development and manufacturing organization (CDMO), since 2020.

Fertin is a specialist in innovative oral and intra-oral delivery technologies.

Mr Halling has previously held international executive roles at Novozymes, Ingredion and Doehler Group.

ALK  announced a new executive VP for R&D, Henriette Mersebach, at the end of 2022.